Company Overview of Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
8840 Wilshire Boulevard
Beverly Hills, CA 90211
Founded in 2005
Key Executives for Capricor Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $232.3K
Executive Vice President, General Counsel and Secretary
Total Annual Compensation: $189.4K
Compensation as of Fiscal Year 2013.
Capricor Therapeutics, Inc. Key Developments
Capricor Therapeutics, Inc. Appoints Thomas Copmann as Vice President of Regulatory Affairs and Drug Development
Feb 27 15
Capricor Therapeutics, Inc. announced that Thomas Copmann, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs and Drug Development. In this role, Dr. Copmann will lead the company's regulatory initiatives and strategy, ensure appropriate regulatory compliance in the conduct of all Capricor development programs and
manage reporting to the FDA and health authorities. Prior to joining Capricor, Dr. Copmann served as chair of the Commission on Drugs for Rare Diseases, was the industry representative on the National Vaccine Advisory Board and served as a scientific advisor to President George H.W. Bush.
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
Jan 12 15
Capricor Therapeutics, Inc. announced that the first three patients have been treated in its DYNAMIC clinical trial. The trial is being conducted by Dr. Raj Makkar and his colleagues at Cedars-Sinai Heart Institute in Los Angeles. The Phase I DYNAMIC trial, also known as the 'Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells' trial, will evaluate CDCs (CAP-1002) in patients with advanced heart failure. The Phase I trial is being funded in part through a grant of approximately $3 million from the National Institutes of Health (NIH). The Phase I trial will enroll 14 patients with either ischemic or non-ischemic dilated cardiomyopathy with left ventricular ejection fraction (LVEF) = 35% and New York Heart Association (NYHA) Class III or Ambulatory Class IV heart failure. Suitable patients will undergo sequential intracoronary infusion (triple vessel infusion) of CAP-1002 in up to three coronary territories. The primary safety endpoints will be assessed at the 1-month visit. Safety and exploratory efficacy endpoints including ejection fraction, ventricular volumes and a six-minute walk test will be evaluated at both the 6 and 12 month follow-up. It is hoped that following the successful 14 patient lead-in phase of DYNAMIC, the safety results will support continuation to a subsequent phase that includes a randomized, control cohort. Capricor is concurrently conducting the 300 patient, Phase II ALLSTAR trial with CAP-1002 in patients thirty days to one year following large myocardial infarctions (heart attack). ALLSTAR is designed to determine safety and effectiveness at scar size reduction of CAP-1002 in patients at high risk following myocardial infarction. Phase II of the ALLSTAR trial is being funded with the support of the California Institute for Regenerative Medicine.
Capricor Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015
Jan 8 15
Capricor Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 3, 2015
January 9, 2015